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 This article discusses the important role of nuclear medicine 
imaging and therapy in the management of neuroendocrine 
tumours (NETs). Somatostatin receptor scintigraphy has a 
high impact on patient management versus conventional 
imaging. Molecular radiotherapy is an important part of the 
management of patients with NETs. Selection of patients for 
molecular radiotherapy in NETs is based on uptake on their 
radionuclide imaging study. The imaging agent has the same 
mechanism of uptake as the therapeutic agent. Thus, the im-
aging study preselects patients that are likely to concentrate 
radiation within their tumours. 
 Introduction 
 Neuroendocrine tumours (NETs) represent a spectrum of 
tumours that can arise from various parts of the body and have 
variability in clinical presentation. They are often classified by 
embryonic origin into foregut, midgut and hindgut tumours. 
Foregut tumours develop in the respiratory tract, thymus, 
stomach, duodenum and pancreas; midgut tumours develop 
in the small bowel, appendix, caecum and ascending colon; 
hindgut tumours develop in the transverse colon, descending 
colon, sigmoid colon or rectum. 1 NETs have a spectrum of 
presentations, ranging from well differentiated to poorly 
differentiated tumours, functioning to non-functioning and 
have variable proliferative activity. 2 The tumour differentiation, 
grading (based on tumour proliferation and mitotic activity) 
and the site of primary tumour are important factors in making 
therapeutic decisions in management of NET patients. 
 Unlike many cancers, large proportions of NETs tend 
to be slow growing and are not associated with increased 
metabolic activity. These are therefore not visualised on 
fludeoxyglucose (FDG) positron emission tomography/
computerised tomography (PET/CT). Other functional 
imaging techniques have thus been employed to stage NETs 
and determine suitability for molecular radiotherapy. Despite 
variability in presentation, NETs have similar properties in 
that the majority of well-differentiated and some high-grade 
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of somatostatin receptor (SSR) expression. This high degree of 
SSR expression and neuroamine concentration can be exploited 
both in terms of imaging and therapy with radiolabelled 
somatostatin analogues and radiolabelled catecholamine 
analogue meta-iodobenzyl guanidine (MIBG). 3,4 
 Selection of patients for molecular radiotherapy is based 
on uptake on their radionuclide imaging study. In nuclear 
medicine, theranostics is a combination of a diagnostic agent 
and a therapeutic agent where the target imaged/treated is the 
same. The imaging agent has the same mechanism of uptake 
as the therapeutic agent. Thus, the imaging study pre-selects 
patients that are likely to concentrate radiation within their 
tumours. The imaging and therapeutic radiopharmaceutical 
forms a theranostic pair. This article discusses the important 
role of radionculide imaging and radionculide therapy in the 
management of NETs based on these mechanisms. An algorithm 
of the management of NETs is shown in Fig  1 , with the lower left 
box highlighting the role of radiolabelled SSR and MIBG in the 
management of NETs. FDG PET/CT may be useful in predicting 
response to peptide receptor radionuclide therapy (PRRT) and 
in determining progression-free survival with those with FDG 
positive well differentiated having worse survival. 
 Key points 
 Somatostatin receptor scintigraphy plays an important role in 
the management of NETs, providing more accurate staging 
and determining whether patients are eligible for cold or 
radiolabelled somatostatin analogues 
 PRRT is an effective treatment in well-differentiated NETs with 
limited toxicity 
 MIBG imaging is a well established imaging modality for 
catecholamine secreting neuroectodermal tumours 
 131I-MIBG therapy is an effective treatment in metastatic 
neuroectodermal tumours, but has generally been replaced by 
PRRT in NETs 
 Access to PRRT varies across the UK 
 KEYWORDS:  177 Lu,  90 Y, MIBG, PRRT, somatostatin receptor 
scintigraphy ■
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 Somatostatin receptor scintigraphy 
 SSR imaging has a major role to play in imaging of NETs and 
is now integral to their management, allowing more accurate 
staging and demonstrating suitability for therapies (‘cold’ or 
radiolabelled somatostatin analogues). 5 SSRs are expressed 
in a number of normal cells, including the pituitary gland, 
thyroid, spleen and kidney. In addition, several tumours have 
been found to express SSRs. In particular, NETs have been 
shown to have a high incidence and density of receptors. 6 Five 
SSR subtypes have been identified with subtype-2 the most 
overexpressed receptor in NETs. 
 Somatostatin receptor scintigraphy was first introduced in the 
late 1980s and subsequently there have been many variations 
in the radiopharmaceuticals used to image the SSR. 7 There are 
two components to the SSR analogue: the radionuclide and the 
somatostatin analogue peptide, linked by a chelator. 
 Single photon emission computerised tomography 
gamma camera somatostatin receptor scintigraphy 
 The first somatostatin analogue used for imaging of NETs 
was octreotide and this remains as one of the most popular 
analogues for imaging NETs. Octreotide labelled with 
Indium-111 ( 111 In) is commercially available as Octreoscan® 
and remains the most popular SSR imaging agent.  111 In has 
a half-life of 68 hours and delayed imaging (24–48 hours) is 
usually required to ensure reduction in background activity 
caused by clearance via the renal and hepatobiliary system. 
Labelling of somatostatin analogues with the most commonly 
used radionuclide in nuclear medicine  99m Technetium ( 99m Tc) 
has also been achieved, allowing single day imaging. 8 
 Uptake of Octreoscan® and  99m Tc-HYNIC-peptides is seen in 
the majority of patients (>75%) with NETs; major exceptions 
include poorly differentiated NETs (because of a lower 
expression of SSR-2) and insulinomas with a reduced sensitivity 
of 50–70% (probably because of small tumour size or poor 
expression of SSR-2 receptor). 9 
 PET somatostatin receptor scintigraphy 
 The development of a generator producing PET radionuclide 
gallium-68 ( 68 Ga) has been the biggest evolution in SSR 
imaging over the past decade, becoming increasingly more 
popular in centres where PET/CT imaging is available.  68 Ga 
has a convenient physical half-life of 68 minutes and decays 
by positron emission, giving the advantages of increased 
sensitivity and resolution that modern PET imaging allows. It 





























 Fig 1.  An algorithm of the therapeutic options in NETs based on the United Kingdom and Ireland Neuroendocrine Tumour Society (UKINETS) 
and Royal Free Algorithm . 1  123 I = Iodine-123;  177 Lu = Lutetium-177;  90 Y = Yttrium-90; MIBG = meta-iodobenzyl guanidine; NET = neuroendocrine tumour; 
OLT = orthotopic liver transplantation; PRRT = peptide receptor radionuclide therapy; SIRT = selective internal radiation therapy; SSR = somatostatin 
receptor ; 
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lasts 7–12 months and can be eluted (to produce  68 Ga) twice a 
day. The  68 Ga radiopeptide study is completed within 2–3 hours 
of administration of tracer. In addition, the patient effective 
radiation dose is less than half that of  111 In-DTPA-octreotide. 10 
 68 Ga has been linked with three main somatostatin analogues 
(via linker DOTA): DOTA-TATE, DOTA-NOC and DOTA-
TOC. 11 The main differences between these compounds 
are small changes in the peptide side chain, which result in 
different affinities to the five SSR subtypes. 
 There is no doubt that  68 Ga-DOTA-peptides represent 
a significant evolution in SSR imaging over  111 In-DTPA-
octreotide imaging. In a study, it was shown that  68 Ga-
DOTA-TATE changed the management in 36 out of the 51 
(70%) patients who had either no uptake (35 patients) or 
low-grade uptake (15 patients) of  111 In-octreotide. 12 A recent 
meta-analysis demonstrated a pooled sensitivity of 93% and 
specificity of 96% in staging well-differentiated NETs with an 
impact in management of approximately 50%. 13 
 Peptide receptor radionuclide therapy 
 PRRT is the term commonly used to describe treatment with 
β-emitting radiolabelled somatostatin analogues: the peptide 
receptor being the SSR. PRRT has been performed with various 
somatostatin analogues labelled with  111 In, Yttrium-90 ( 90 Y) 
and Lutetium-177 ( 177 Lu). From these, three main agents have 
developed: 
 1  90 Y-DOTA octreotide ( 90 Y-DOTATOC) 
 2  90 Y-DOTA octreotate ( 90 Y-DOTATATE) 
 3  177 Lu-DOTA octreotate ( 177 Lu-DOTATATE). 
 The radionuclides involved have different physical 
characteristics, which may have a bearing on both their efficacy 
and toxicity, ie  90 Y has a higher energy beta particle emission 
than  177 Lu, and thus may be suited to treating larger tumour 
masses but has more toxicity. 
 90 Y-DOTATATE/DOTATOC anti-tumour effects 
 Partial response or disease stabilisation has been reported 
between 70 and 80%. 14–17 In addition, the majority of studies have 
shown excellent symptomatic response in >70% of patients. Time 
to progression in reported studies ranged from 13–29 months. 
 Toxicity 
 The main toxicities of  90 Y-PRRT are myelosuppression and 
renal impairment. The rate of permanent renal toxicity showed 
variation (range 1–9%). The greatest recorded significant 
permanent renal toxicity is quite high at 9% from a Swiss study 
of over 1,000 patients. 14 The predictors for severe renal toxicity 
by the Swiss study included advancing age, baseline glomerular 
filtration rate and high uptake of tracer by the kidneys on the 
baseline Octreoscan®. 
 Bone marrow toxicity is seen in approximately 12% of 
patients overall and is usually transient, presenting as either 
thrombocytopenia or leucopenia. Mild to moderate liver 
toxicity has also been recorded in 1% of patients all of whom 
had extensive bi-lobar liver metastases. 
 177 Lu-PRRT anti-tumour effects 
 Several studies have shown that  177 Lu-PRRT is a useful 
treatment and it has now become the most popular form of 
PRRT because of its efficacy and low toxicity (Table  1 ). 18–21 
The most notable published study is a recent phase III 
multicentre international study (NETTER-1) that is the first 
randomised controlled trial in PRRT. This trial has completed 
recruitment and was published in early 2017. 20 This is a 
randomised comparator controlled study comparing standard 
activity of  177 Lu-DOTATATE with high dose octreotide LAR 
60 mg (which is a non-radioactive somatostatin analogue 
used in the management of NET patients, Fig  1 ) in patients 
with inoperable, progressive, SSR positive, midgut carcinoid 
tumours. The results have been extremely promising, 
demonstrating a progression-free survival of approximately 
40 months versus 8.4 months for octreotide LAR. This appears 
to be far superior to other systemic treatment modalities for 
metastatic disease in NETs. An example of a patient with a 
positive  68 Ga-DOTATATE study who went on to have  177 Lu- 
DOTATATE therapy is demonstrated in Fig  2 . A patient with 
a partial response to  177 Lu-DOTATATE therapy is shown in 
Fig  3 . 
 Toxicity 
 Data from the largest reporting centre demonstrated WHO 
Grade 3/4 haematological toxicity in 9.4% of 504 patients. 18 
Of these, two patients (0.4%) developed renal insufficiency. 
There were three patients with serious liver toxicity. One of 
these patients (with diffuse liver metastases) died of hepatic 
failure. Four patients developed myelodysplastic syndrome, 
one of which was likely to be related to previous alkylating 
chemotherapy. Similarly NETTER-1 data showed that <10% 
of patients developed myelosuppression. 
 Table 1.  Studies evaluating the efficacy of  177 Lu-DOTATATE 
Study Patients, n Location CR /PR PD Time to progress, months Median OS, months 
Kwekkemboom  et al 18  310 (504) Rotterdam 91/301 (30%) 61/310 (20%) 33 46
Pencharz  et al 19 79 London 10/79 (13%) 18 (23%) 28 -
Claringbold  et al (plus 
capecitabine) 23 
33 Perth 24% 6% 88% at 24 months
NETTER-1 study 20 116 Multicentre: 
Europe and 
USA
18% 5% 40 months estimate
 177 Lu = Lutetium-177; CR = complete response; OS = overall survival; PD = progressive disease; PR = partial response 
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local therapies (eg radiofrequency ablation and embolisation) 
and radiotargeted therapies including PRRT. 
 The key component to patient selection for PRRT is the SSR 
scan. Sufficient uptake within tumours on the somatostatin 
receptor scintigraphy provides evidence that the tumours 
are likely to concentrate radioactivity in sufficient quantities 
to achieve tumour damage (theranostic principle). Based 
on SSR imaging, the liver is commonly used as the reference 
point (the liver having tracer uptake related to hepatic peptide 
metabolism). Uptake greater than that seen in the background 
liver in the majority of disease (ie >90%) is generally considered 
sufficient to proceed with PRRT. 
 Patient selection for PRRT in NETs includes patients who have 
histologically proven NET, who are SSR positive and have no 
surgical cure possible or patients who are unsuitable for surgery. 
Patients should have sufficient bone marrow reserve, ie platelets 
>90,000/µL for  90 Y and >75,000/µL for  177 Lu. 24 Additionally, 
significant renal impairment is a relative contraindication, 
particularly if  90 Y-radiopeptides are being used. 
 Those with extensive disease, eg extensive liver/bone 
metastases, tend to have worse outcomes with PRRT. Similarly, 
it has been shown that significantly poorer outcomes occur in 
patients with poor baseline functional status. 18 Grading of the 
tumour also has a role in treatment with PRRT, as patients with 
G3 tumours should have platinum-based chemotherapy rather 
than PRRT as first-line therapy. 
 FDG PET/CT may be useful in predicting response to PRRT 
and in determining progression-free survival, with those with 
 Combination PRRT therapies 
 Combination therapies have been used in PRRT, either combining 
different radionuclides (ie  90 Y and  177 Lu-labelled peptides) or 
combining PRRT with radiosensitising chemotherapy. 
 Combination dual radiopeptide therapies have been performed 
as tandem therapies (ie administrating a combination of  90 Y and 
 177 Lu-radiopeptides at a single sitting) or sequential therapies 
with  90 Y and  177 Lu-radiopeptides. 22,23 Combination PRRT have 
been shown to prolong survival over single agent PRRT. 22,23 
However, these studies were non-randomised retrospective 
reviews and there was potential selection bias in the groups. 
 Treatment with radiosensitising chemotherapy has also 
been reported to improve the success of PRRT, with disease 
response/stabilisation seen in 96% of patients. 21 
 Patient selection for PRRT in NETs 
 The therapeutic options in NETs should be discussed in 
a multidisciplinary setting, with the choice of the most 
appropriate technique made. In the majority of patients surgical 
resection offers the only realistic possibility of cure and thus 
this should be considered the preferred option if curative 
surgery is feasible and the patient is fit enough. 
 In patients with unresectable metastatic disease there are 
various therapeutic options available. These include surgical 
debulking, chemotherapy, molecular targeted therapies (eg 
sunitinib and everolimus), interferon, somatostatin analogues, 
A B
 Fig 2.  A patient with pancreatic, liver and skeletal metastases . A –  68 Ga-DOTATATE maximal intensity projection image demonstrating pancreatic 
primary tumour (red arrow) with liver (orange arrow) and small volume skeletal metastases (blue arrow); B –  177 Lu-DOTATATE post-therapy image showing 
the same biodistribution . 
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FDG positive G1/G2 tumours having worse progression-free 
survival. 25 
 As NETs can be slow growing, the timing of treatment can be 
debatable. Patients with progressive disease or patients who are 
symptomatic despite cold somatostatin analogues should be the 
patients considered for therapy. 
 Practical considerations of PRRT 
 Approximately 50% of the radiopeptide is excreted in urine 
during the first 6–8 hours. Thereafter, minimal urinary 
excretion is seen and the main radiation protection issues 
are related to the low-abundance gamma rays emitted. 
Thus, patients are advised of standard radiation protection 
precautions, eg sleeping in a separate room to their partner, 
avoiding close contact with young children or pregnant 
women. 
 The majority of procedures are well tolerated and, in some 
centres in the UK, are performed as day cases. Care has to be 
taken in patients with functioning syndromes, eg VIPOMAs 
or symptomatic carcinoid syndrome, and thus it’s safer to treat 
these patients as inpatients. 
 MIBG imaging and therapy 
 MIBG is an alkylguanidine (catecholamine analogue); it enters 
the cell membrane via the norepinephrine transporter and 
is then transported and stored in neurosecretory granules 
through the vesicular monoamine transporter. 26–28 MIBG 
was first described for imaging of NETs in the late 1970s with 
 131 I-MIBG. 29 Radio-iodinated MIBG is well established in 
the detection of catecholamine-secreting neuroectodermal 
tumours (phaeochromocytoma and paraganglioma), with 
overall sensitivity around 90%. MIBG imaging has also been 
used in NETs, with rates of positivity at around 70%. 4 In several 
studies comparing  123 I-MIBG and  111 In-pentetreotide,  111 In-
pentetreotide was found to be more sensitive for the detection of 
disease in NETs. 30–32 The majority of NETs are thus not imaged/
staged with MIBG but with somatostatin receptor scintigraphy. 
Although MIBG imaging may not be useful in staging a NET 
patient, it may be useful in determining if the patient can be 
treated with  131 I-MIBG radionuclide therapy – ie do all/majority 
of tumours have sufficient uptake to concentrate a β-emitting 
radiation within their tumours. 33–35  131 I-MIBG is a β-emitting 
radionuclide with the β particle having a maximum range of 2.3 
A B C
 Fig 3.  A patient with bilobar liver metastases .  68 Ga-DOTATATE maximal intensity projection image demonstrates intense uptake in bilobar liver 
metastases (A). The red arrow points to a target liver lesion. The patient had  177 Lu-DOTATATE therapy. Post-therapy planar  177 Lu-DOTATATE studies 
performed after the ﬁ rst (B) and third (C) cycle of treatment demonstrate a signiﬁ cant reduction in the majority of liver lesions with the target liver lesion 
having signiﬁ cantly reduced uptake, consistent with a good response to treatment . The orange arrow represents physiological activity in the gallbladder. 
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mm. This agent has been shown to stabilise disease in patients 
with progressive metastatic disease. An example of a patient 
with good uptake on the MIBG imaging scan that went on to 
have MIBG therapy is demonstrated in Fig  4 . 
 Approximately 40–50% of patients develop good symptomatic 
response to treatment. 33–35 Not many studies evaluated 
progression-free survival, but most studies showed a median 
overall survival of over 40 months following MIBG therapy. 
Interestingly, Sywak  et al compared two groups of patients 
with midgut NETs. 36 The first group (n=58) was treated in a 
centre where  131 I-MIBG was available while the second group 
(n=59) had no access to  131 I-MIBG (or other radio-targeted 
treatments). The 5-year survival rate in the first group was 63% 
versus 47% in the second group (p=0.1) 
 131 I-MIBG toxicity 
 The main toxicities are bone marrow suppression and 
myelodysplasias. Grade 3/4 bone marrow toxicity was seen 
in approximately 8% of patients (range 2–25%) with some 
relationship between the administered activity and the degree 
of toxicity. The most common form of bone marrow toxicity 
was thrombocytopenia (11%) followed by leucopenia (10%). 
Myelodysplasia is another possible rare side effect, which may 
occur in patients heavily pre-treated with chemotherapy or 
radiotherapy. 33–35 
 Tumour and critical organ dosimetry 
 Dosimetry is the measurement of absorbed radiation 
dose imparted by ionising radiation. Dosimetry can be 
performed both to calculate critical organ radiation dose 
(to limit toxicity) and to optimise tumour dose. Critical 
organ activity-limiting toxicity is usually myelotoxicity and 
red marrow dosimetry is therefore of particular relevance. 
This is a challenging procedure that can be addressed by 
performing whole-body dosimetry as a surrogate measure, 
which can be derived accurately from external measurements 
(gamma camera whole-body imaging). 37 Varying patient 
biokinetics lead to a wide range of reported absorbed 
whole-body doses. 38,39 An even wider range of absorbed 
doses is delivered to tumours for all therapy procedures. 
Ilan  et al found from three single photon emission CT scans 
tumour absorbed doses ranging from 10–340 Gy and found 
a significant correlation between the absorbed dose and 
tumour reduction. 40 
 As personalised medicine and image-guided treatments 
(theranostics) are further introduced into clinical practice, 
dosimetry-based treatment is a promising avenue for further 
exploration via multicentre clinical trials to optimise the 
therapeutic procedure. 
 Current status of PRRT in the UK 
 Currently PRRT is not funded by NHS England. It was removed 
from the cancer drugs fund in November 2015 although 
funding for PRRT is still available through NHS Wales and 
NHS Scotland. Access to PRRT in England is principally 
limited to clinical trials and in a small number of patients on 
a compassionate use basis. Based on the NETTER-1 study, 
it is expected that  177 Lu-DOTATATE will receive European 
marketing authorisation (EMA) later this year. Currently, the 
National Institute for Health and Care Excellence is appraising 
the use of  177 Lu-DOTATATE, but formal guidance will only be 
published after EMA approval. 
 Conclusions 
 Nuclear medicine imaging and therapy plays a vital role 
in management of NETs. SSR imaging provides enhanced 
accuracy in staging with accuracies of > 90% in well 
differentiated tumours and allows change in management 
compared with conventional imaging. Radionuclide therapies 
with radiolabelled somatostatin analogues and radio-iodinated 
MIBG provide symptomatic benefit and increase survival in 
patients with metastatic NETs. It is in NETs that the theranostic 
concept first became popularised. ■ 
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A B
 Fig 4.  Anterior images of a  123 I-meta-iodobenzyl guanidine (MIBG) study 
(A) and  131 I-MIBG post-therapy image (B) . This patient with progressive 
metastatic midgut neuroendocrine tumour has uptake in their liver and right 
infraclavicular nodal metastases on  123 I-MIBG study. They subsequently had 
 131 I-MIBG therapy and had stable disease after three cycles. 
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